We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $439M
1-Year Est. Return 289.78%
This Fund
S&P 500
This Quarter Est. Return
+35.32%
1 Year Est. Return
+289.78%
3 Year Est. Return
+622.25%
5 Year Est. Return
+856.34%
10 Year Est. Return
+2,866.87%
AUM
$439M
AUM Growth
+$76.4M
Cap. Flow
-$4.42M
Cap. Flow %
-1.01%
Top 10 Hldgs %
28.21%
Holding
185
New
29
Increased
50
Reduced
66
Closed
38

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$4.61M
2
ALKS icon
Alkermes
ALKS
+$4.14M
3
TNGX icon
Tango Therapeutics
TNGX
+$3.85M
4
RLMD icon
Relmada Therapeutics
RLMD
+$3.12M
5
ELVN icon
Enliven Therapeutics
ELVN
+$2.75M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$6.03M
2
NUVL
Nuvalent
NUVL
+$5.8M
3
SLNO
Soleno Therapeutics
SLNO
+$5.53M
4
SYRE icon
Spyre Therapeutics
SYRE
+$5M
5
APGE
Apogee Therapeutics
APGE
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 70.95%
2 Technology 8.26%
3 Miscellaneous 6.43%
4 Industrials 4.96%
5 Financials 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTR icon
151
Avantor
AVTR
$10.1B
– –
-186,500
Closed -$1.46M
BKNG icon
152
Booking.com
BKNG
$145B
– –
-7,075
Closed -$1.19M
BZ icon
153
Kanzhun
BZ
$7.56B
– –
-21,298
Closed -$285K
CAAP icon
154
Corporacion America
CAAP
$3.99B
– –
-29,745
Closed -$752K
CLF icon
155
Cleveland-Cliffs
CLF
$7.13B
– –
-102,474
Closed -$866K
CLH icon
156
Clean Harbors
CLH
$16.7B
– –
-5,543
Closed -$1.59M
CNTA
157
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-5,964
Closed -$237K
CPNG icon
158
Coupang
CPNG
$27.5B
– –
-46,036
Closed -$869K
CRM icon
159
Salesforce
CRM
$213B
– –
-8,313
Closed -$1.55M
EQT icon
160
EQT Corp
EQT
$34.5B
– –
-18,290
Closed -$1.16M
INTU icon
161
Intuit
INTU
$91B
– –
-3,003
Closed -$1.3M
JAZZ icon
162
Jazz Pharmaceuticals
JAZZ
$16B
– –
-10,838
Closed -$2.05M
KRC icon
163
Kilroy Realty
KRC
$4.32B
– –
-41,997
Closed -$1.18M
MMM icon
164
3M
MMM
$86.9B
– –
-6,150
Closed -$893K
NATL icon
165
NCR Atleos
NATL
$3.41B
– –
-40,100
Closed -$1.75M
NOK icon
166
Nokia
NOK
$56.2B
– –
-70,824
Closed -$569K
NUVL
167
DELISTED
Nuvalent
NUVL
– –
-56,602
Closed -$5.8M
PBR.A icon
168
Petrobras Class A
PBR.A
$118B
– –
-59,400
Closed -$1.11M
PFSI icon
169
PennyMac Financial
PFSI
$3.81B
– –
-7,306
Closed -$639K
P
170
Everpure Inc
P
$33.1B
– –
-14,009
Closed -$827K
PTC icon
171
PTC
PTC
$15.3B
– –
-7,474
Closed -$1.06M
RLX icon
172
RLX Technology
RLX
$2.2B
– –
-311,700
Closed -$686K
RXO icon
173
RXO
RXO
$3.41B
– –
-43,038
Closed -$629K
SE icon
174
Sea Limited
SE
$68.7B
– –
-7,450
Closed -$617K
SLNO
175
DELISTED
Soleno Therapeutics
SLNO
– –
-165,227
Closed -$5.53M
4 5 6
7
8

Similar funds

OGM
OnyxPoint Global Management New York $439M AUM 52.19% 1-Year Est. Return
NCM
New Capital Management Houston, Texas $439M AUM 16.55% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $438M AUM 64.84% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
CNC
Citizens & Northern Corp Wellsboro, Pennsylvania $438M AUM 26.63% 1-Year Est. Return
TAA
Turiya Advisors Asia Hong Kong $440M AUM 152.81% 1-Year Est. Return
PMA
Prudent Man Advisors Naperville, Illinois $438M AUM 34.49% 1-Year Est. Return
FW
Fairway Wealth Independence, Ohio $437M AUM 19.74% 1-Year Est. Return

HighVista Strategies's Q2 2026 Portfolio in Review

As of Q2 2026, HighVista Strategies held 185 positions worth $439M, up 21% from $362M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies's Q2 2026 filing shows 29 new, 50 increased, 66 reduced and 38 closed positions. Its largest new stake was C4 Therapeutics: 1,348,136 shares worth $6.3M. The largest sale was Terns Pharmaceuticals, an estimated $6.03M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier, followed by Technology and Miscellaneous.

  • HighVista Strategies's largest Q2 2026 buy was C4 Therapeutics: 1,348,136 shares worth $6.3M.
  • HighVista Strategies added most to Alkermes in Q2 2026, an estimated $4.14M increase.
  • HighVista Strategies's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $5M.
  • HighVista Strategies fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $6.03M.
  • HighVista Strategies's ten largest holdings make up 28% of its $439M portfolio in Q2 2026.
  • HighVista Strategies opened 29 new positions and closed 38 in Q2 2026.
  • HighVista Strategies's portfolio value rose 21% quarter-over-quarter to $439M.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.